Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Active:	Yes
Cancer Type:	Lung Cancer Unknown Primary	NCT ID:	NCT06422143
Trial Phases:	Phase III	Protocol IDs:	2870-023 (primary) NCI-2025-00211 2023-510128-66 2023-510128-66-00 jRCT2021240015 MK-2870-023 U1111-1301-2790
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp & Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06422143

Summary

This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane
(paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance
sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous
non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance
sacituzumab tirumotecan is superior to pembrolizumab without sacituzumab tirumotecan
maintenance with respect to overall survival (OS).

Objectives

All participants undergo an initial induction phase of four cycles, each cycle consisting
of pembrolizumab q3w + carboplatin q3w + paclitaxel q3w or nabpaclitaxel weekly.
Participants are then randomly assigned to pembrolizumab maintenance vs. pembrolizumab +
sac-TMT maintenance.

Treatment Sites in Georgia

City of Hope Atlanta
600 Celebrate Life Parkway
Newnan, GA 30265
770-400-6169
www.cityofhope.org/locations/atlanta/atlanta-cancer-center

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.